Provista Diagnostics Closes $5.25 Million Financing

New York, March 21, 2016 -- NEW YORK, NY – March 21, 2016 - Provista Diagnostics, Inc., a company developing and commercializing proteomic-based diagnostic, prognostic and monitoring tests for cancers affecting women, today announced the closing of an additional $5.25 Million in preferred funding. This funding is comprised of capital gained from existing investors exercising warrants from a previous financing. The proceeds will be used for continued commercial development, prospective clinical trials, key management hires and general corporate purposes.

“We are grateful to our investors for believing in Provista’s mission as we bring to market the next generation of diagnostics to improve women’s health,” said Provista President and CEO David Reese, Ph.D. “These investments will help produce new diagnostic tests for early cancer detection to aid physicians in making more accurate diagnoses that will ultimately help produce more precise outcomes for patients.”

Provista has raised a total of $37.9 Million since 2011.

About Provista Diagnostics, Inc.

Provista Diagnostics is a privately held molecular diagnostics company headquartered in New York focused on developing and commercializing a new generation of proprietary blood-based diagnostic, prognostic and monitoring tests designed to address the unmet needs in cancers affecting women, such as breast and gynecologic cancers. Provista Diagnostics’ state-of-the-art, high complexity clinical laboratory is accredited by the College of American Pathologists (CAP) and certified by the Centers for Medicare and Medicaid Services (CMS) to be compliant with the Clinical Laboratory Improvement Amendments (CLIA).

Additional information about Provista Diagnostics is available at ProvistaDx.com

Information about Provista Diagnostics’ clinical trials is available at ClinicalTrials.gov

Safe Harbor Statement

Statements contained in this communication not relating to historical facts are forward-looking statements that are intended to fall within the safe harbor rule for such statements under the Private Securities Litigation Reform Act of 1995. The information contained in the forward-looking statements is inherently uncertain, and Provista’s actual results may differ materially due to a number of factors, many of which are beyond Provista’s ability to predict or control, including among others, viability and effectiveness of our sales approach and overall marketing strategies, the outcome of development or regulatory review of our products, commercial success or acceptance by the medical community, competitive responses, our ability to raise additional capital, and the ability to successfully file a registration statement with the SEC. These forward-looking statements are subject to known and unknown risks and uncertainties that could cause actual events to differ from the forward-looking statements. Provista operates in a highly competitive and rapidly changing business and regulatory environment, thus new or unforeseen risks may arise. Accordingly, investors should not place any reliance on forward-looking statements as a prediction of actual results. Except as is expressly required by the federal securities laws, Provista undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, changed circumstances or future events or for any other reason.

Susan LaMacchia
Provista Diagnostics
212-202-3174
[email protected]